The tomosynthesis option for the Siemens’ MAMMOMAT Inspiration digital mammography system received FDA approval.
The U.S. FDA has approved the tomosynthesis option for Siemens Healthcare’s MAMMOMAT Inspiration digital mammography system, Siemens announced today.
The add-on option includes Siemens’ breast tomosynthesis algorithm, which reconstructs multiple 2D images of the breast into an approximation of a 3D image, enabling detection of tumors that are hidden by overlapping breast tissue, Siemens said in a release. The resulting 3D image enables more accurate diagnosis than standard 2D mammography and reduces the number of false-positives, Siemens said.
Limitations in conventional analog mammography and full-field digital mammography include the display of a 3D structure of the breast on a 2D level, which hampers the physicians’ ability to identify certain types of tumors, Siemens explained in the release. In tomosynthesis mode, the X-ray tube of the MAMMOMAT Inspiration system rotates in a circular motion around the breast to acquire an image every two degrees, while moving through an angular range of 50 degrees, the release said. The resulting 25 projections are reconstructed as 3D digital breast tomosynthesis images.
This dataset will help clinicians better analyze the type and size of breast lesions, as well as microcalcifications, Siemens said.
“We know that in clinical practice, this increased diagnostic accuracy [of tomosynthesis] also means fewer diagnostic biopsy procedures and fewer anxiety-inducing recalls, which typically contributes to both improved patient outcomes and reduced cost,” Gregory Sorenson, MD, president and CEO of Siemens Healthcare North America, said in the release.[[{"type":"media","view_mode":"media_crop","fid":"34515","attributes":{"alt":"Siemens Healthcare’s MAMMOMAT Inspiration ","class":"media-image media-image-right","id":"media_crop_8474416794736","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"3679","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 213px; width: 160px; float: right;","title":"Siemens Healthcare’s MAMMOMAT Inspiration ","typeof":"foaf:Image"}}]]
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.